ExoDiscovery
LiquiDyne sample collection kit

Precise monitoring.
Reproducible recovery.
2-day results.

ExoDiscovery's exosome liquid-biopsy platform reads RNA biomarkers protected inside extracellular vesicles. 10,000× more sensitive than conventional ctDNA methods, from 20 µL of plasma, in 2 days.

Published in ACS Nano (2025). Validated in a lung cancer patient cohort.

Validated performance
{{ s.value }}{{ s.note }}
{{ s.value }}{{ s.note }}
{{ s.label }}
{{ s.vs }}

Method: published preliminary study, internal case-control, blind, retrospective design, 83 samples from 73 patients with lung cancer and 10 healthy donors. Source: Clarissa EM et al., ACS Nano 2025, 19(5), 5526-5538. Study results may not reflect real-world outcomes.

Platform portfolio

ExoDiscovery Portfolio

One isolation core. Three products.

Evidence

Rigorously Peer-reviewed Publications

{{ pub.journal }} {{ pub.year }}

{{ pub.title }}

{{ pub.authors }}

{{ pub.desc }}

View paper
LiquiDyne™ · Liquid biopsy platform

LiquiDyne™ Platform

Exosomes with 1-week half-life
Direct RNA analysis
Only 20 µL sample required
2-day results

Conventional Methods

ctDNA with 2-hour half-life
PCR/NGS amplification required
10-20 mL sample volume
7-14 day turnaround time

Sample handling is automated, which is what keeps a 20 µL read reproducible across sites.

Platform capabilities

Six things LiquiDyne does

Removing the tissue block, the isolation step and the amplification step changes what a monitoring assay can do.

{{ c.num }}

{{ c.claim }}

{{ c.why }}

Evidence
{{ c.evidence }}

Plasma is separated from a standard EDTA draw. The assay reads 20 µL of it.

Vesicles are enriched on a disc, with no lysis, extraction or amplification.

Biomarker panel

From one gene to seven

EGFR carried the feasibility work. The same chemistry reads any target with a molecular beacon, so the panel expands without changing the workflow.

{{ p.gene }}

{{ p.variants }}

{{ p.why }}

EGFR L858R and T790M are the targets validated in the published cohort. KRAS, BRAF, ROS1, MET, RET and EML4-ALK are in development and have no published performance figures on this platform yet. Research use only. Not available for clinical diagnostic use.

Serial monitoring

Four patients, 33 draws

The published serial cohort followed four patients on EGFR-targeted therapy. In two of them, T790M rose in plasma before the resistance mutation was confirmed by the standard tissue or ctDNA route. In the other two, no T790M appeared, and none was found by any method.

{{ c.id }} {{ c.flag }}
{{ c.who }}
{{ c.dx }}
{{ ph.drug }}
{{ ph.detail }}
{{ c.readout }}

33 serial samples from 4 patients on EGFR-targeted therapy. Timelines describe treatment history and the sequence in which mutations were observed; they are not a quantitative plot of variant levels. One further patient in the cross-sectional cohort showed T790M by this method while it was still undetectable in tissue by the conventional EGFR Mutyper route, later confirmed in bronchoalveolar lavage fluid. Three samples were positive by this method without tissue confirmation and are counted as false positives in the specificity figure above. Source: Clarissa EM et al., ACS Nano 2025. Research use only.

Benchmark

Measured against droplet digital PCR

Both methods were run on the same EV samples spiked into healthy human plasma. ddPCR is the established digital reference, which makes it the honest comparison to publish.

{{ b.k }}
LiquiDyne
{{ b.ours }}
ddPCR
{{ b.theirs }}

Limits of detection for EGFR L858R and T790M measured on H1975-derived EVs spiked into healthy human plasma. ddPCR detected these mutations only above 100,000 EVs/µL under the same comparison. Source: Clarissa EM et al., ACS Nano 2025. Research use only.

Analytical robustness

What holds up in plasma

{{ r.value }}
{{ r.label }}

{{ r.desc }}
Where it sits

Three ways to monitor from blood

Monitoring assays divide by what they read and what they need before the first draw. The distinction that matters clinically is whether a tumour tissue block and a bespoke assay build stand between diagnosis and the first result.

{{ a.tag }}

{{ a.name }}

{{ r.k }}
{{ r.v }}

Comparison is by method class, not by named commercial product. Figures in the LiquiDyne column are from Clarissa EM et al., ACS Nano 2025; figures in the other two columns describe the general characteristics of those approaches and vary by assay and vendor. Research use only. Not a claim of superiority over any specific commercial test.

Proposed study design

Longitudinal therapy management

The question is whether serial vesicle RNA tracks therapy response and resistance emergence ahead of the standard route, in a prospective cohort rather than a retrospective one. The outline below is the starting point for protocol discussion, not a fixed design.

{{ s.num }}

{{ s.title }}

{{ s.when }}

{{ s.detail }}
{{ p.k }}
{{ p.v }}

Endpoints, cohort size, draw intervals and comparator route are open to discussion with participating investigators. Full protocol, statistical analysis plan and sample handling instructions available under a confidentiality agreement. Research use only.

Clinical trial

Enrolling sites now

We are recruiting investigator sites to take LiquiDyne from published feasibility into prospective monitoring across EGFR, KRAS, BRAF, ROS1, MET, RET and EML4-ALK. Protocol, eligibility criteria and sample logistics on request.
Science

Why the vesicle is the sample

Exosomes are 30-200 nm lipid-bilayer vesicles shed by nearly every cell type. That membrane is the whole point: it protects the cargo inside from circulating nucleases and proteases, which is what makes exosomes useful in two otherwise unrelated ways: as a diagnostic readout, and as a regenerative payload.

Vesicle work is ordinary bench work once the isolation step is reliable.

Diagnostic qualities

Read the signal

A one-week half-life in circulation

Cell-free tumour DNA degrades within about two hours of release. Membrane-bound EV cargo persists for roughly a week, so a routine draw-and-ship workflow still yields a readable sample.

Cargo inherits the parent cell

Tumour-derived vesicles carry tumour RNA. Mutation calling therefore works from blood, without a tissue biopsy, and the same vesicle can be re-sampled longitudinally as therapy changes.

No amplification, no amplification bias

Protected RNA is abundant enough to read directly by droplet-digital counting, removing the PCR/NGS enrichment step where allele-frequency distortion and turnaround time both accumulate.

Present in every accessible fluid

Plasma, serum, urine and cell-culture media all carry EVs, so sampling is a standard blood draw rather than a procedure.

Regenerative qualities

Deliver the signal

Growth factors in bioavailable form

Platelet-derived vesicles carry PDGF, TGF-β and VEGF packaged in a lipid membrane, which shields them from proteolysis and supports uptake by recipient cells.

Cell-free by construction

The vesicle fraction delivers the paracrine signal without live cells, so engraftment, viability and cold-chain handling stop being constraints on the protocol.

Autologous by default

Prepared from the patient's own platelet-rich plasma, the material carries the patient's own surface markers, so the immunogenicity question that limits allogeneic approaches does not arise.

Dose is a function of recovery

Conventional PRP protocols do not control the vesicle fraction, so delivered dose varies between operators. Reproducible isolation is what turns a preparation into a protocol.

Publications

Peer-reviewed record

{{ pub.journal }} {{ pub.year }}

{{ pub.title }}

{{ pub.authors }}

{{ pub.desc }}

View paper
Collaborators & validation partners
Products

One core, three products

Centrifugal microfluidics recovers extracellular vesicles without ultracentrifugation. What sits downstream of that recovery is what separates the three.

{{ p.tag }}

{{ p.name }}

{{ p.long }}

{{ r.k }}
{{ r.v }}
Powered by ExoDisc

Chairside in under an hour

Concentrates the exosome fraction of the patient's own platelet-rich plasma, at the practice, from a single draw. One workflow across equine and canine practice, on the same ExoDisc isolation core.

{{ sp.name }}

One method, two patient sizes. The canine protocol runs the same steps on the same disc and the same bench device as the equine protocol, with draw volume, disc count and final volume scaled down. Nothing else about the workflow changes.

Species
Equine, canine
Draw
One, scaled to patient
Yield
Up to 6 mL equine
Prep time
Under 1 hour
Setting
Chairside, no send-out

For veterinary use. Canine yield scales with patient size and draw volume.

Enriched PRP

Same draw.
More exosomes.

ExoPRP concentrates the vesicle fraction on purpose, so what goes into the patient is defined rather than incidental.

Applications

Two indications, two species

Osteoarthritis and wound healing are where regenerative preparation already sits in veterinary practice. ExoPRP changes what it takes to offer it, not what it is for.

{{ a.species }} {{ a.tag }}

{{ a.title }}

{{ a.body }}

{{ a.point }}

For veterinary use.

Workflow

Draw to joint, one visit

The patient stays on site. Nothing ships to a lab, and the preparation is administered the same day it is made.

01

Draw

A single whole-blood collection at the practice. Standard tubes, standard handling.

02

Prepare

The platelet fraction is concentrated and activated at the bench, following the supplied protocol.

03

Enrich

One ExoDisc-V disc spins in the LabSpinner Rotor and delivers the enriched exosome fraction.

04

Administer

Autologous ExoPRP, allocated joint-wise by the attending veterinarian.

Draw volume, disc count, and final volume scale with the patient; canine protocols run the same steps at reduced scale. Detailed method parameters are provided to pilot sites under agreement, with training. Preparation characteristics depend on the patient's own platelet-rich plasma.

The system

What runs at the bench

LabSpinner Rotor

Bench rotor device

A benchtop unit that runs on ordinary mains power. Touch panel, one mode selection, one run button.

ExoDisc-V

Single-use disc

Six units per disc, built on published fluid-assisted separation technology. Room-temperature storage, 9-month shelf life. No ultracentrifuge and no columns.

Two scales

Equine and canine

One workflow, two patient sizes. The canine protocol runs the same steps on the same disc and device, with draw volume and disc count scaled down.

Included

Complimentary quality check

We offer a complimentary quality check on specimens run at your practice, so consistency is measured rather than assumed. Enquire when you set up.

Sponsored pilot

Pilot at your clinic

If you would like to try our ExoPRP, partner with us for a tailored pilot study!
About ExoDiscovery

Precision diagnostics.
Faster answers.

ExoDiscovery laboratory

Better outcomes, earlier

Our technology harnesses the natural protective power of exosomes, cell-derived vesicles containing preserved genetic material, to provide insight into cancer presence and progression.

The platform offers 10,000× greater sensitivity than conventional testing methods, enabling detection of cancer-specific biomarkers with exceptional accuracy. This represents a significant advancement in liquid biopsy capability, with potential to transform how cancer is detected, monitored, and treated.

Through continued innovation and partnerships with leading medical institutions, ExoDiscovery is working to ensure the technology reaches the patients who need it most.

Scientific leadership

{{ p.num }}

{{ p.text }}
Locations

Where we work

{{ c.country }}

{{ c.city }}

{{ c.role }}
Leadership team

Who runs ExoDiscovery

{{ l.name }}

{{ l.role }}

{{ l.full }}

LinkedIn
Contact

Partner with us

We respond within 1-2 business days with quotes, technical information, and protocol support.

{{ o.tag }}
{{ o.entity }}
{{ o.address }}
{{ o.email }}
Thank you. Your submission has been received.

We respond within 1-2 business days.

{{ formError }}

By submitting you agree to be contacted about ExoDiscovery products and research.
Newsroom

News and notes

Publications, platform notes, and how we think about evidence. Select any post to read it here.

{{ p.cat }} {{ p.date }} {{ p.readTime }}

{{ p.title }}

{{ p.excerpt }}
{{ p.cat }} {{ p.date }} {{ p.readTime }} ExoDiscovery Team

{{ p.title }}

{{ p.excerpt }}

{{ para }}
Sourcing

{{ p.sourcing }}

Share
Subscribe

Get new posts by email

Publications and platform notes when they go out. No more than once a month.

You are on the list. Thank you.

This form is a design template and does not transmit data.
Support

Questions

Something not covered here? Get in touch.
Support

Questions

Something not covered here? Get in touch.

{{ f.a }}

Talk to us

One exosome platform across clinical monitoring, laboratory isolation, and veterinary regenerative preparation. Tell us which one you need.